CoChat
Sign Up
Cited by 347Posttraumatic Stress Disorder ResearchSleep and related disordersMigration, Health and Trauma

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review

Open access
Berger, William, Mendlowicz, Mauro V., Marques-Portella, Carla, Kinrys, Gustavo, Fontenelle, Leonardo F., Marmar, Charles R., Figueira, Ivan·2009·Progress in Neuro-Psychopharmacology and Biological Psychiatry
DOI 10.1016/j.pnpbp.2008.12.004PMC PMC2720612
Open this paper in CoChat — free account

Abstract

The selective serotonin reuptake inhibitors (SSRIs) are considered the first-line pharmacological treatment for PTSD. However, even when treated with this class of drugs, response rates rarely exceed 60% and less than 20-30% of the patients achieve full remission. The aim of this study was to address this limitation by systematically reviewing the options left for the treatment of PTSD when patients do not respond satisfactorily to or tolerate SSRIs. A systematic review covering all original articles, letters and brief reports published in any language until October 2008 was conducted through searches in the ISI/Web of Science, PubMed and PILOTS databases. The search terms included the pharmacological class of each agent or its generic name plus "PTSD" or "stress disorder" in the title, in the abstract or as a keyword. Sixty-three articles were selected, covering the following categories: antipsychotics, anticonvulsants, adrenergic-inhibiting agents, opioid antagonists, benzodiazepines and other agents. None of the identified agents reached the level A of scientific evidence, 5 reached level B, 7 level C and 13 level D. The non-antidepressant agent with the strongest scientific evidence supporting its use in PTSD is risperidone, which can be envisaged as an effective add-on therapy when patients did not fully benefit from previous treatment with SSRIs. Prazosin, an adrenergic-inhibiting agent, is a promising alternative for cases of PTSD where nightmares and insomnia are prominent symptoms. So far, there is no consistent empirical support for using benzodiazepines in the prevention or in the treatment of PTSD, although these drugs could alleviate some associated non-specific symptoms, such as insomnia or anxiety. Further controlled clinical trials and meta-analysis are needed to guide clinicians in their search of effective pharmacological alternatives to antidepressants in PTSD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2008.12.004

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 137 references

Research works printed but not linked: 1

  1. Forster, 1995, Lithium for irritability in posttraumatic-stress-disorder, J Trauma Stress, 8, 143, 10.1002/jts.2490080110 · DOI

Cited by

Sorted by citations

See all 347

Related

Metadata

Authors
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Cambridge Health Alliance (US)
  • San Francisco VA Medical Center (US)
Corresponding author
Berger, William
ORCID
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2009-03
Volume
33
Issue
2
Pages
169-180
ISSN
0278-5846 (ISSN-L)
DOI
10.1016/j.pnpbp.2008.12.004
PMC
PMC2720612
OpenAlex
W1977428298
Cited by
347
References
137
Citations by year
2026: 14 · 2025: 12 · 2024: 29 · 2023: 26 · 2022: 28 · 2021: 41 · 2020: 27 · 2019: 15 · 2018: 24 · 2017: 12 · 2016: 17 · 2015: 16 · 2014: 16 · 2013: 17 · 2012: 18
FWCI
2.01
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Australian Government
  • Governo Brasil
  • National Institute of Mental Health (MH056350-06, R01MH056350)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
Keywords
post-traumatic stress disorder, pharmacotherapy, antidepressants, selective serotonin reuptake inhibitors, risperidone, prazosin, benzodiazepines, antipsychotic drugs, antiepileptic drugs, opioid antagonists, treatment-resistant PTSD, nightmares, insomnia, adjunctive therapy
MeSH terms
Animals, Anticonvulsants, Antidepressive Agents, Benzodiazepines, Humans, Narcotic Antagonists, Stress Disorders, Post-Traumatic, Antipsychotic Agents, Adrenergic Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review